These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 17299078

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.
    Bajaj M, Suraamornkul S, Kashyap S, Cusi K, Mandarino L, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4649-55. PubMed ID: 15356076
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individuals.
    Daniele G, Eldor R, Merovci A, Clarke GD, Xiong J, Tripathy D, Taranova A, Abdul-Ghani M, DeFronzo RA.
    Diabetes; 2014 Aug; 63(8):2812-20. PubMed ID: 24353180
    [Abstract] [Full Text] [Related]

  • 6. Effect of Dapagliflozin With and Without Acipimox on Insulin Sensitivity and Insulin Secretion in T2DM Males.
    Merovci A, Abdul-Ghani M, Mari A, Solis-Herrera C, Xiong J, Daniele G, Tripathy D, DeFronzo RA.
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1249-56. PubMed ID: 26765576
    [Abstract] [Full Text] [Related]

  • 7. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.
    Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, Wajchenberg BL.
    Diabetes; 1999 Sep; 48(9):1836-41. PubMed ID: 10480616
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
    Pontiroli AE, Manzoni MF, Malighetti ME, Lanzi R.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
    [Abstract] [Full Text] [Related]

  • 10. Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes.
    Kashyap SR, Belfort R, Berria R, Suraamornkul S, Pratipranawatr T, Finlayson J, Barrentine A, Bajaj M, Mandarino L, DeFronzo R, Cusi K.
    Am J Physiol Endocrinol Metab; 2004 Sep; 287(3):E537-46. PubMed ID: 15126243
    [Abstract] [Full Text] [Related]

  • 11. The nicotinic acid analogue acipimox increases plasma leptin and decreases free fatty acids in type 2 diabetic patients.
    Worm D, Vinten J, Vaag A, Henriksen JE, Beck-Nielsen H.
    Eur J Endocrinol; 2000 Sep; 143(3):389-95. PubMed ID: 11022182
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults.
    Segerlantz M, Bramnert M, Manhem P, Laurila E, Groop LC.
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5813-8. PubMed ID: 11739444
    [Abstract] [Full Text] [Related]

  • 13. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.
    Paolisso G, Tagliamonte MR, Rizzo MR, Gualdiero P, Saccomanno F, Gambardella A, Giugliano D, D'Onofrio F, Howard BV.
    Diabetologia; 1998 Oct; 41(10):1127-32. PubMed ID: 9794097
    [Abstract] [Full Text] [Related]

  • 14. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
    Cordido F, Peino R, Peñalva A, Alvarez CV, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.
    Segerlantz M, Bramnert M, Manhem P, Laurila E, Groop LC.
    Eur J Endocrinol; 2003 Dec; 149(6):511-9. PubMed ID: 14640991
    [Abstract] [Full Text] [Related]

  • 16. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R, Cordido F, Peñalva A, Alvarez CV, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [Abstract] [Full Text] [Related]

  • 17. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
    Worm D, Henriksen JE, Vaag A, Thye-Rønn P, Melander A, Beck-Nielsen H.
    J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
    [Abstract] [Full Text] [Related]

  • 18. Metabolic and endocrine consequences of acute suppression of FFAs by acipimox in polycystic ovary syndrome.
    Ciampelli M, Muzj G, Leoni F, Romualdi D, Belosi C, Cento RM, Lanzone A.
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5324-9. PubMed ID: 11701699
    [Abstract] [Full Text] [Related]

  • 19. Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects.
    Qvigstad E, Mostad IL, Bjerve KS, Grill VE.
    Am J Physiol Endocrinol Metab; 2003 Jan; 284(1):E129-37. PubMed ID: 12485810
    [Abstract] [Full Text] [Related]

  • 20. Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes.
    Boden G, Chen X.
    Diabetes; 1999 Mar; 48(3):577-83. PubMed ID: 10078559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.